We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
- Authors
Maillart, Elisabeth; Louapre, Céline; Lubetzki, Catherine; Papeix, Caroline
- Abstract
We report two cases of multiple sclerosis (MS) patients with natalizumab-associated progressive multifocal leukoencephalopathy. Severe MS relapses occurred between four and five months after natalizumab discontinuation. After failure of immunomodulatory treatment, both patients were treated with fingolimod. The outcome was positive on clinical and MRI disease activity, without worsening of the progressive multifocal leukoencephalopathy. These observations suggest that using fingolimod for severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy may be an option, under close clinical and radiological monitoring.
- Subjects
PROGRESSIVE multifocal leukoencephalopathy; NATALIZUMAB; FINGOLIMOD; MULTIPLE sclerosis; MEDICAL imaging systems; PATIENTS
- Publication
Multiple Sclerosis Journal, 2014, Vol 20, Issue 4, p505
- ISSN
1352-4585
- Publication type
Case Study
- DOI
10.1177/1352458513516530